Cenobamate is indicated for the adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/06/2021|
|Rapid review completed||05/07/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cenobamate compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||22/07/2021|
|Pre-submission consultation with Applicant||06/09/2021|
|Full HTA submission received from Applicant||13/12/2021|
|Preliminary review sent to Applicant||27/04/2022|
|NCPE assessment re-commenced||27/05/2022|
|Factual accuracy check sent to Applicant||04/08/2022|
|NCPE assessment re-commenced||11/08/2022|
|NCPE assessment completed||06/10/2022|
|NCPE assessment outcome||The NCPE recommends that cenobamate (Ontozry®) be considered for reimbursement as a second- or subsequent-line adjunctive treatment of focal onset seizures in adult patients with epilepsy who have failed treatment with two or more previous anti-seizure medicines, including at least one adjunctive therapy*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.